Unichem Laboratories Ltd
Unichem Laboratories Q2 Results 2026 (FY27): Revenue ₹401.90 Cr, PAT ₹32.85 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Get Unichem Laboratories Ltd's next results in your feed
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Unichem Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated).
As stated in Unichem Laboratories Ltd's Q2 FY27 results statement · published 4 Nov 2026. Reported figures, not investment advice.
Based on Unichem Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Quarterly Financials (Q2 FY27 ended 30th September 2026):.
From Unichem Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Unichem Laboratories' revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated).
- Revenue from operations for the quarter ended 30.09.2025 was ₹356.90 crores (standalone) and ₹578.96 crores (consolidated).
- Year-on-year revenue growth for the quarter is approximately:
2 more points from Unichem Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Unichem Laboratories' margins in Q2 FY27?
See what Unichem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Unichem Laboratories planning?
See what Unichem Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Unichem Laboratories raising money or cutting debt?
See what Unichem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Unichem Laboratories' order book?
See what Unichem Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Unichem Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹633 Cr, net profit ₹41 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Unichem Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Zim Laboratories (Q2 FY27)
Total Operating Income for Q2 FY27: ₹1,054 Mn, up 18.9% YoY from ₹887 Mn in Q2 FY26 (Page 5, 10). Key investor presentation takeaways from Zim Laboratories Ltd'
- Aurobindo Pharma (Q2 FY27)
Quarterly revenue for Q2FY27: ₹10,263 Cr, up 23.9% YoY (Page 6, 7, 13). Key investor presentation takeaways from Aurobindo Pharma Ltd's Q2 FY27 investor present
- SMS Pharmaceuticals (Q2 FY27)
Q2FY27 revenue from operations: ₹316.08 crore, a 30% year-on-year (YoY) increase from ₹242.43 crore in Q2FY26 (Page 29, 6). Key investor presentation takeaways
- Biocon Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY . Key investor presentation takeaways from Biocon Ltd's Q2 FY27 investor presentation — and how it ranks a
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Unichem Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Unichem Laboratories Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Quarterly Financials (Q2 FY27 ended 30th September 2026):.
What is Unichem Laboratories Ltd share price analysis?
Unichem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 29.1 with a market cap of ₹3,558 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Unichem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.